News Conference News TCT 2025 DOAC May Be Safer Than DAPT After Left Atrial Appendage Closure: ANDES Yael L. Maxwell November 04, 2025
News Conference News TCT 2025 ENCIRCLE: Good Results With Sapien M3 Transseptal TMVR Todd Neale October 27, 2025
News Conference News TCT 2025 Tendyne Safely Reduces MR in Patients With Severe Calcification: SUMMIT-MAC Yael L. Maxwell October 27, 2025
News Conference News TCT 2025 More Data on Tricuspid Valve Interventions Reassure, yet Questions Remain Yael L. Maxwell October 26, 2025
News Conference News TCT 2025 TTVR Remains Safe, Effective in Presence of CIED Leads Todd Neale October 25, 2025
News Opinion Editor's Corner TCT 2025 What’s Going to Be Hot at TCT 2025 Michael O'Riordan October 09, 2025
News Conference News TCT 2024 Percutaneous Mechanical Aspiration Promising for Right-Heart Infective Endocarditis Caitlin E. Cox November 08, 2024
News Conference News TCT 2024 Few Patients Under 65 Get TAVI: Those Who Do Are Especially Sick Yael L. Maxwell November 07, 2024
News Conference News TCT 2024 Co-STAR Hints That Colchicine May Curb Rhythm Disturbances After TAVI Michael O'Riordan November 06, 2024
News Conference News TCT 2024 After TAVI, Single Antiplatelet Better Than Dual: TRITAVI Registry Yael L. Maxwell November 05, 2024
News Conference News TCT 2024 Vascular Closure via Suture/Plug Combo Reduces Complications: ACCESS-TAVI Caitlin E. Cox November 04, 2024
News Conference News TCT 2024 Pooled All-Female Analysis Support Benefits of TAVI Over SAVR L.A. McKeown November 01, 2024
News Conference News TCT 2024 Embolic Protection Benefits Varied by Geography in PROTECTED TAVR Todd Neale October 31, 2024
News Conference News TCT 2024 TRISCEND II: Full Results a Win for TTVR in Severe Tricuspid Regurgitation Michael O'Riordan October 30, 2024
News Conference News TCT 2024 ACURATE IDE Trial Misses Primary Endpoint in All-Risk TAVI Patients Todd Neale October 30, 2024
Presentation TCT 2024 CV Event Reduction is the Essential Criterion for Implementing New Device Therapies Presenter: Ori Ben-Yehuda October 30, 2024
Presentation TCT 2024 One-year Outcomes of ACURATE neo2 vs Approved TAVR Devices in All-risk patients with Severe AS: the ACURATE IDE Trial Presenter: Michael Reardon October 30, 2024
Presentation TCT 2024 TCT 916: MÉTIS Study: Modification of NEurological Outcome After TAVR UsIng Sentinel Protection Device Presenter: Tomas Kovarnik October 30, 2024
Presentation TCT 2024 Left Atrial Appendage Closure with a Novel Fluoropolymer-Coated Device: The HEAL-LAA Post-Approval Clinical Study Presenter: Seun Alli October 30, 2024
Presentation TCT 2024 One-Year Follow-Up of the US Early Feasibility Study Evaluating Rotational Closure of the LAA Using the Laminar Device Presenter: Saibal Kar October 30, 2024